Are there specific precautions for nivolumab injection site?

What happens at the injection site during nivolumab treatment

Nivolumab is given as an intravenous infusion, not a local injection, so patients do not experience typical subcutaneous injection-site reactions such as swelling or pain at a needle entry point. Instead, clinicians watch for infusion-related reactions that occur during or shortly after the drug enters the bloodstream. These reactions can include fever, chills, flushing, or rare cases of anaphylaxis that require immediate medical attention.

Why are infusion-related reactions important to monitor

These reactions stem from the immune checkpoint blockade mechanism of nivolumab, which activates T-cells and may trigger cytokine release. Cytokine release can produce temporary symptoms that are graded by severity. Grade 1 and 2 reactions usually manage with temporary pause and symptomatic treatment; Grade 3 and 4 reactions require permanent discontinuation. [1]

How long does an infusion-related reaction last

Most symptoms appear during the first or second infusion and settle quickly once the flow rate is slowed or the drug is paused. Subsequent infusions require slower rates and premedication with diphenhydramine, acetaminophen, and sometimes corticosteroids if past reactions occurred. Premedication protocols are protocol-specific and vary by institution.

What happens if an infusion reaction occurs

If a reaction occurs, nurses stop the flow, keep the line open with normal saline, and call a physician. The patient is observed until symptoms disappear. When the patient resumes the treatment, they do not receive a needle “injection” at any fixed site; the same vein or an alternate vein is used for the nächsten infusate.

When does the patent for nivolumab expire

Nivolumab’s compound patent expires in the United States in 2028, with pediatric exclusivity extending it to 2029. [2]